The buildout of a facility ends with technology choices but starts with a purpose, vision, and people, says Roche’s Genentech.   Genentech — part of the Roche Group — broke ground on a $450 million expansion at its Oceanside, California site in February 2023; a site it says will work in unison with the recently completed $250 million Clinical Supply Center in South San Francisco (SSF).  But when thinking about building a facility, the question “where are we going with the…

Resilience has reduced operations at a former Sanofi plant in Massachusetts, following the ending of its contract to manufacture enzyme replacement therapy, Cerezyme. Contract development manufacturing organization (CDMO) National Resilience has said it is reducing operations at its 310,000 square-foot plant in Allston, Massachusetts, which it acquired from Sanofi in February 2021. Sanofi itself added the facility through the $20.1 billion acquisition of Genzyme in 2011. The decision to reduce operations at the facility comes after the contract to manufacture…

Agilent Technologies has started construction to double manufacturing capacity of therapeutic nucleic acids in Frederick, Colorado. According to the research, development, and manufacturing firm, the facility will create over 160 life sciences jobs in the Frederick location. Additionally, the investment will bolster US production for active pharmaceutical ingredients (APIs) that are used to treat a wide range of illnesses, such as cancer, infectious diseases, and cardiovascular diseases. “Agilent has had a growing presence in Colorado for more than 20 years.…

Myeloid Therapeutics has been selected to operate an RNA research and pilot manufacturing plant at Macquarie University in Sydney, Australia. The facility, which will be located at Macquarie University’s Wallumattagal campus, has been called the “first-of-its-kind” in Australia by the New South Wales (NSW) government.  The partnership between Myeloid and the NSW  Government aims to support the State’s ability to develop and produce RNA-based therapeutics and vaccines locally. “The cutting-edge work that will be done at this world-leading facility has…

Oxford will acquire National Resilience’s manufacturing facility in Marlborough, Massachusetts and then lease the property back to the CDMO. Global real estate investor Oxford Properties Group (Oxford) says the purchase and lease back of the 120,000 square-foot biomanufacturing facility from and to contract development manufacturing organization (CDMO) Resilience will expand its North American footprint while raising proceeds for the CDMO. “This is a financing transaction that has no impact to operations. Resilience has sold the real estate of the site…